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ABSTRACT
Aim. Drug-induced parkinsonism (DIP) is the most common form of parkinsonism after Parkinson’s disease (PD) itself. It has 
been widely believed that DIP is characterised by symmetry of symptoms. Studies of patients with DIP in whom PD had been 
ruled out by SPECT-DaTSCAN have shown that symptom asymmetry is a common element of DIP clinical presentation. The aim 
of our study was to determine whether the asymmetry of symptoms in DIP is related to any abnormality within the presynaptic 
part of the nigrostriatal dopaminergic system.
Materials and methods. Eleven patients with the diagnosis of DIP and asymmetric symptoms were studied. Their individual 
SPECT-DaTSCANs were normal. Indices calculated for the whole group of radiotracer uptake in the whole striatum, putamen and 
caudate contralateral to more severe DIP symptoms were compared to values obtained in the opposite hemisphere.
Results. We did not find significant differences in radiotracer uptake in structures contralateral to more severe clinical symptoms 
when compared to the homolateral hemisphere.
Conclusions. Our results have not confirmed the presence of a presynaptic nigrostriatal deficit which could be related to 
asymmetry of DIP. The factors responsible for the asymmetry of DIP symptoms should be sought in the postsynaptic part of the 
nigrostriatal dopaminergic system.
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Introduction
Idiopathic Parkinson’s disease (PD) and drug-induced 
parkinsonism (DIP) are the two most common forms of 
parkinsonism [1, 2]. In PD, motor symptoms are caused by 
neurodegeneration of presynaptic neurons of the nigrostriatal 
dopaminergic system, while DIP is related to the post-synaptic 
dopaminergic receptor blockade within the striatum. The 
differential diagnosis of PD and DIP can be a challenge, espe-
cially in older people, because increasing age is a recognised 
as a risk for both these conditions [1, 2]. It is very important 
to identify persons with PD in a group of patients taking 
dopamine receptor blocking agents (DRBA) and in whom par-
kinsonism has developed because the treatment and prognosis 
are completely different. Therefore, attention has been paid to 
differences in the clinical presentations of PD and DIP, which 
could be useful in differential diagnosis. It has generally been 
assumed that DIP is characterised by symmetry of symptoms, 
the absence of rest tremor, and the co-occurrence of bucco-
-linguo-masticatory dyskinesia and akathisia [1–3].
123I-Ioflupane (DaTSCAN®, GE Healthcare) is a dopamine 
transporter (DAT) radioligand for single-photon emission 
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tomography (SPECT). A SPECT-DaTSCAN is used as a marker 
of integrity of the presynaptic part of the nigrostriatal dopami-
nergic system [4, 5]. Studies of patients diagnosed with DIP, in 
whom SPECT-DaTSCAN had excluded the coexistence of PD, 
have shown that the symptomatology of these two conditions 
shows many similarities and that asymmetry of symptoms is 
common in DIP [6–9]. The aim of our study was to determine 
whether the asymmetry of symptoms in DIP is related to any 




Our study initially enrolled 13 consecutive patients who 
underwent SPECT-DaTSCAN for the differential diagnosis 
between DIP and PD. In two of these subjects the imaging 
revealed abnormalities consistent with neurodegenerative 
parkinsonism. The remaining 11 patients (eight females and 
three males, mean age 64 years) were included into the study. 
All of them presented at least two of the three main (bradyki-
nesia, rigidity, rest tremor) parkinsonian symptoms, and these 
symptoms were either asymmetric or unilateral. Subjects with 
signs suggesting an atypical parkinsonian syndrome, or other 
neurological conditions, were not included.
The duration of exposure to drugs implicated in DIP 
ranged from 2-14 years, while parkinsonian symptoms had 
lasted from 1-84 (mean 18.6) months. The onset of parkin-
sonism was subacute or chronic. The time from the start of 
psychiatric treatment to the development of parkinsonian 
symptoms ranged from 3-24 months. Patients were treated 
with different drugs and some of them received two or more 
drugs at the same time. The drugs most commonly used in 
this group at the time of the evaluation of parkinsonism were 
risperidone, aripiprazole, olanzapine and perazine. 
SPECT-DaTSCAN
SPECT/CT acquisitions were performed with double-head 
hybrid gamma-camera Infinia Hawkeye GE 4 h after i.v. ad-
ministration of 5 mCi of 123I-Ioflupane. Prior to radiotracer 
injection, patients received orally potassium iodine to block 
thyroid uptake of free radioactive iodide. Data was acquired 
with the use of low energy high resolution (LEHR) collima-
tors in dual energy window: 159 keV ± 10% (scatter: 130 keV 
± 10%), in 128 × 128 matrix. Using a step-and-shoot method, 
120 projections lasting 45 s each were registered with the use 
of zoom equal 1.5. Images reoriented to the orbitomeatal plane 
were reconstructed with the OSEM method (2 iter., 10 sub., 
postfilter: Butterworth 0.50/10) with scatter correction and 
attenuation correction (Chang method).
The analysed SPECT-DaTSCAN variables were 123I-
Ioflupane uptake ratios in the entire striatum, putamen and 
caudate in both hemispheres. SPECT-DaTSCAN images were 
analysed semi-quantitatively by a nuclear medicine physician 
expert in neuroimaging. The quantitative assessment of 
DaTSCAN-SPECT images was made using DaTQUANT 
delivered by GE Healthcare.
In order to ascertain the relationship between the asym-
metry of clinical symptoms of DIP and the result of the SPECT-
DaTSCAN, the indices of radiotracer uptake in the whole 
striatum, putamen and caudate contralateral to more severe 
symptoms were compared to the respective values obtained in 
the opposite hemispheres. Moreover, putamen/caudate ratios 
for both sides were calculated.
The distribution of indices of tracer uptake obtained on 
both sides in each structure were compared by means of the 
Wilcoxon test for paired samples.
Results
The individual SPECT-DaTSCAN results of all patients 
were considered to be normal. Indices of 123I-Ioflupane 
uptake in the whole striatum, putamen and caudate for both 
sides, as well as the values of the putamen/caudate ratio, are 
presented in Table 1.
Discussion
DIP is the most common form of parkinsonism after PD 
[1, 2]. The diagnosis of DIP is relatively easy provided that 
there is an unequivocal temporal relationship between the 
DRBA introduction and the occurrence of parkinsonism, and 
even more so if discontinuation of offending drug leads to the 
resolution of DIP symptoms. 
However, DIP can develop gradually after prolonged ex-
posure to neuroleptic and, moreover, DIP can persist despite 
discontinuation of the drug. In such cases, it may be suspected 
that the patient being treated with DRBA develops PD, and the 
neuroleptic only contributes to its earlier manifestation. This 
is referred to as ‘unmasking of PD by DRBA’ [8, 10]. 
Both for the psychiatrist and for the neurologist it is crucial 
to decide whether the patient has pure DIP or Parkinson’s 
disease, the course of which could have been modified by the 
DRBA administration. The differential diagnosis between PD 
and DIP can be challenging, especially because both forms of 
pathology can co-exist. This applies primarily to the elderly 
population.
In the past, this differentiation was based on clinical 
symptoms. It was widely believed that DIP is characterised 
by symmetry of symptoms, lack of tremor or the presence of 
postural tremor, the occurrence of bucco-lingual-masticatory 
dyskinesia, and akathisia [1–3]. 
In clinical practice, a SPECT-DaTSCAN is performed to 
differentiate between neurodegenerative parkinsonisms (e.g. 
PD) on the one hand, and on the other hand parkinsonian 
syndromes without presynaptic involvement (e.g. DIP) of 
the nigrostriatal dopaminergic system [9, 11, 12]. Studies of 
patients with DIP in whom the co-existence of PD has been 
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Table 1. Results of DaTSCAN imaging. Indices of radiotracer uptake (normalised to nonspecific uptake in occipital cortex) the whole striatum, putamen and 
caudate are presented. Moreover, putamen/caudate ratios for both sides were calculated
Structure Side Indices of radiotracer uptake  p*
Mean ± SD Minimum-maximum Median
Striatum Contralateral 2.54  0.29 1.85–2.94 2.61 0.59
Ipsilateral 2.57  0.32 1.79–2.97 2.64
Putamen Contralateral 2.41  0.31 1.74–2.80 2.47 0.51
Ipsilateral 2.44  0.32 1.64–2.82 2.51
Caudate Contralateral 2.83  0.32 2.12–3.25 2.91 0.88
Ipsilateral 2.86  0.34 2.09–3.26 2.94
Putamen/caudate Contralateral 0.89  0.07 0.81–1.02 0.88 0.72
Ipsilateral 0.89  0.03 0.86–0.98 0.88
Contralateral — side opposite to the side where the symptoms of DIP were more severe; Ipsilateral — side where the symptoms of DIP were more severe; *Wilcoxon test for paired samples
ruled out by SPECT-DaTSCAN have shown that symptom 
asymmetry is a not uncommon element of DIP clinical 
presentation.
Some authors have reported asymmetry of symptoms to be 
less common than symmetry in DIP [6, 7], while others have 
not found significant differences in asymmetry of tremor, bra-
dykinesia and stiffness between patients with a normal and an 
abnormal SPECT-DaTSCAN [8]. A recently published study 
[9] revealed asymmetry of symptoms in 88% of subjects with 
a diagnosis of DIP and a normal SPECT-DaTSCAN. The cause 
of the asymmetry of DIP symptoms has never been studied 
or discussed to date.
The term ‘unmasked PD’ has not been clarified so far. It 
was usually used for cases when the symptoms of parkinso-
nian syndrome appeared after neuroleptic administration and 
where the SPECT-DaTSCAN showed asymmetric deficit of the 
presynaptic part of the nigrostriatal system.
Prospective studies carried out in patients with REM Sleep 
Behaviour Disorder (RBD), which is a pre-motor manifesta-
tion of PD and other synucleinopathies, have shown that nigro-
striatal dopaminergic deficit is a slowly but steadily increasing 
phenomenon in the early phase of the disease [13, 14]. In RBD 
subjects who remained parkinsonism free, 123I-Ioflupane 
uptake reduction was more pronounced in the putamen than 
it was in the caudate nucleus [13]. It can be assumed that even 
at an early, premotor stage of PD, when the individual SPECT-
-DaTSCAN result remains within the normal range, there may 
be a subtle asymmetry in the number of dopaminergic cells 
in the substantia nigra, and that this asymmetry is unmasked 
when the patient develops DIP. However, our results seem to 
exclude this possibility.
Conclusions
Our results have not confirmed the presence of a presynap-
tic nigrostriatal deficit which could be related to asymmetry 
of DIP.
Future directions
The factors responsible for the asymmetry of DIP symp-
toms should be sought in the postsynaptic part of the nigro-
striatal dopaminergic system.
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